is tirzepatide off the shortage list Resolved? FDA Says Yes, Compounders No What is the latest update

Epidemiologic data suggest that a sustained 5 mmHg reduction in systolic blood pressure correlates with approximately 10% lower risk of major cardiovascular events and 7% reduction in all-cause mortality, though it's important to note that cardiovascular outcome trials for tirzepatide are ongoing and definitive cardiovascular benefit has not yet been established

A responsive design that adapts well across various devices, ensuring accessibility for all users

References Anderson, B

Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy

GLP-1 is a natural hormone that helps control appetite and boost weight loss, while Ozempic is an effective medication that mimics GLP-1s effects for lasting results